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Introduction: Current guidelines recommend up to 12 months dual antiplatelet therapy (DAPT) after drug-eluting stents 
(DES) implantation, however optimal DAPT duration after DES implantation is still a matter of debate. We aimed to 
evaluate clinical outcomes with short-term (<12 months) DAPT as compared to standard 12-months DAPT in patients 
treated with DES. 
Method: In December 2013, we searched PubMed and conference proceedings for randomized trials directly comparing 
short-term (<12 months) versus 12-months DAPT after DES implantation. Random-effects meta-analyses were performed 
comparing clinical outcomes at 12 months in patients allocated to short-term DAPT and patients allocated to 12-months 
DAPT. Heterogeneity was assessed with I-squared. The primary safety and efficacy endpoints were bleeding and the 
composite of cardiac death and myocardial infarction, respectively. The secondary safety endpoint was definite or 
probable stent thrombosis according to ARC criteria. 
Results: We identified 3 trials: EXCELLENT (6-months vs. 12-months DAPT, N=1,443), RESET (3-months vs. 12-months 
DAPT, N=2,117), and OPTIMIZE (3-months  vs. 12-months DAPT, N=3,119) – including a total of 6,679 patients with 12-
months follow-up. At 12 months, short-term DAPT was associated with a reduced risk of any bleeding (RR 0.68, 95%CI 
0.47-1.00) and a trend towards a reduced risk of major bleeding (RR 0.59, 95%CI 0.30-1.10) as compared to 12-months 
DAPT. With respect to efficacy, risks cardiac death or myocardial infarction (RR 1.10, 95%CI 0.82-1.47) and stent 
thrombosis (RR 1.30, 95%CI 0.50-3.36) did not differ between patients allocated to short-term DAPT compared with 12-
months DAPT. Noteworthy, landmark analyses at the time of DAPT interruption showed that risks of cardiac death or 
myocardial infarction (RR 0.96, 95%CI 0.60-1.58) as well as stent thrombosis (RR 1.34, 95%CI 0.17-10.76) did not differ 
between the two groups after DAPT interruption up to 12 months follow-up. No evidence of significant heterogeneity was 
observed across trials for any of the analyzed endpoints. 
Conclusion: Compared with standard 12-months DAPT, short-term DAPT reduces the risk of bleeding without 
compromising efficacy as indicated by similar risks of cardiac death, myocardial infarction and stent thrombosis 
throughout 12-months follow-up. 
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Introduction: Patients undergoing PCI with subsequent need for dual antiplatelet therapy are at risk for gastrointestinal 
bleeding (GIB) complications. 
Method: Between March 2009 and June 2012, 6,190 patients with coronary artery disease underwent PCI at a tertiary 
care center and were prospectively followed for one year. Bleeding was assessed according to the BARC criteria (Type 2-
5). Predictors of bleeding were examined using a case control design (1 case vs 5 controls). All patients were prescribed 
dual antiplatelet therapy consisting of aspirin and clopidogrel for a duration of 12 months, with the exception of STEMI 
patients who were treated with prasugrel instead of clopidogrel since September 2009 and NSTE-ACS patients who were 
treated with ticagrelor instead of clopidogrel since November 2011. 
Results: A total of 210 patients (3.4%) had a bleeding event at one year follow-up, of which 62 (1%) bleeding events were 
due to gastrointestinal bleeding (GIB). GIB bleeding events were categorized as BARC 2 bleeding events in 24%, as 
BARC 3a bleeding events in 29%, and as BARC 3b bleeding events in 46% of cases. ¨ 
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No GIB case was fatal (BARC 5a or b).  In univariate analyses, current smoking (OR 1.9, 95%CI 1.1 – 3.9, p=0.02), 
anemia at admission (OR 1.9, 95%CI 1.05 – 3.5, p=0.035), and history of malignancy (OR 2.4, 95% CI 1.2 – 5.0, p=0.02) 
were predictors of GIB.  In multivariate analyses, history of malignancy emerged as the only independent predictor of GIB 
(OR 2.3, 95% CI 1.0-5.1, p=0.049). 
Conclusion: In this unselected PCI cohort, one third of all bleedings were gastrointestinal with a frequency of 1% at one 
year. History of malignancy emerged as the only independent predictor of GIB. 
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Introduction: Current STEMI guidelines recommend the use of prasugrel in clopidogrel-naïve patients. We assessed the 
safety and efficacy of the concurrent administration of a clopidogrel and prasugrel loading dose (LD) among patients with 
acute STEMI undergoing primary PCI. 
Method: Between September 2009 and October 2012, 2,025 STEMI patients were enrolled into the randomized 
COMFORTABLE AMI trial and the SPUM ACS cohort study. Patients were divided into three groups according to type of 
peri-procedural antiplatelet loading: (1) clopidogrel and subsequent prasugrel LD [CP], (2) prasugrel LD [P] (3) clopidogrel 
LD [C]. Safety was assessed by the composite of BARC type 3, 4, and_5 bleeding and efficacy by the composite of 
cardiac death, nonfatal MI and stroke, both at 30 days. 
Results: Out of 2,025 patients, 428 (21.1%) had received CP, 447 (22.1%) P, and 1,150 (56.8%) C. At 30 days, the 
safety endpoint was observed in 1.9% of CP, 3.1% of P, and 2.9% of C patients (CP vs C adjusted HR_0.91; 95% CI 
0.40-2.03), CP vs P adjusted_HR 0.60; 95% CI 0.24-1.49). The efficacy endpoint tended to occur less frequent among CP 
compared with C patients (1.9% vs. 5.0%, adjusted_HR_0.46; 95% CI 0.20-1.06) and no difference was observed 
between CP and P patients (1.9% vs 2.9%, adjusted HR 0.55; 95% CI 0.21-1.43). 
  
